Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Auner, Holger W.; Iacobelli, S.; Sbianchi, Giulia; Knol-Bout, Cora; Blaise, D.; Russell, Nigel H.; Schaap, N.P.M.; Garderet, L.; Kroeger, Nicolaus

Fulltext:

190028.pdf

Size:

1.751Mb

Format:

PDF

Description:

Publisher’s version

Download

Publication year

2018

Author(s)

Source

Haematologica, 103, 3, (2018), pp. 514-521

ISSN

0390-6078

DOI

https://doi.org/10.3324/haematol.2017.181339

Publication type

Article / Letter to editor

Please use this identifier to cite or link to this item: https://hdl.handle.net/2066/190028

Display more details

Upload full text

Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.

Radboud Repository

Radboud Repository

Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Publication year

Author(s)

Source

ISSN

DOI

Publication type

Organization

Journal title

Volume

Issue

Page start

Page end

Subject

This item appears in the following Collection(s)